Graves' disease (GD) is a common autoimmune endocrine disorder characterized by thyroid hyperplasia and excessive thyroid hormone production[@ref1]. Eye involvement, known as Graves' ophthalmopathy (GO), is the most common extra-thyroidal manifestation of GD[@ref2][@ref3]. GO results from infiltration of the orbit by auto-reactive T-lymphocytes, proliferation of orbital fibroblasts and increased orbital fat[@ref2][@ref3]. This leads to periorbital oedema, lid retraction, proptosis, diplopia and in severe cases, diminution or loss of vision. Clinically recognized GO occurs in about 25-50 smoking cases of GD in Caucasians and may be sight-threatening in 3-5 per cent[@ref2][@ref3][@ref4].

Environmental (smoking and radioactive iodine) and genetic factors are important in the predisposition to GO[@ref4][@ref5][@ref6][@ref7]. Ethnicity is likely to play an important role in the development of GO[@ref4][@ref7][@ref8]. In a study of 155 patients with GD (116 European, 39 Indian), patients of European descent had a 6.4 times higher risk of GO compared to Indians[@ref7]. The presentation of GO also varies in different ethnic groups. Upper eyelid retraction and soft tissue involvement are reported as the commonest manifestations in Caucasians, in contrast to increased risk of exophthalmos and lower lid retraction in Asians[@ref9][@ref10][@ref11]. Studies addressing the prevalence and risk factors of GO in a large population of Indian patients with GD are not available.

In view of the paucity of data, we studied the prevalence, presentation and risk factors for GO in north Indian patients with GD.

Material & Methods {#sec1-1}
==================

*Subjects*: A total of 235 consecutive adult patients with GD (age at onset ≥18 yr) who were referred to the Endocrinology Clinic at the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, over a period of 1.5 years (April 2009 to September 2010), were enrolled. The hospital is a government-subsidized, tertiary care referral centre in north Indian State of Uttar Pradesh. A diagnosis of GD was made on the basis of clinical features of thyrotoxicosis, elevated thyroid hormones, suppressed thyrotropin (TSH) and thyroid ^99m^Technetium-pertechnetate scan evidence of diffuse homogeneous increased uptake in both lobes of the thyroid. All patients provided written informed consent, and institutional ethics committee approval was obtained prior to the start of the study.

*Study procedure*: In each patient, the initial screening for GO was performed by an endocrinologist. Cases with any evidence of ophthalmopathy/activity were then examined in detail by an ophthalmologist for determining the clinical activity and severity. The findings were classified as per the European Group on Graves' Orbitopathy (EUGOGO) recommendations - preliminary case record form[@ref12][@ref13]. The diagnosis of GO was based on the criteria of Bartley and Gorman[@ref14]. A measurement of ≥20 mm using a Hertel\'s exophthlamometer was diagnosed as exophthalmos. The above cut-off has been previously validated in healthy north Indian population[@ref15]. Clinical activity of GO was classified as per clinical activity score (CAS) recommended by EUGOGO[@ref12][@ref13]. A CAS of 0-2 was considered inactive and 3-7 active GO[@ref12][@ref13][@ref16]. Severity of GO was classified into mild, moderate-severe and sight-threatening based on the EUGOGO classification[@ref13].

*Assays*: Serum total T3, total T4 and TSH were estimated by chemiluminescence immunoassay (Immulite 1000, Siemens, USA). Serum TSH receptor antibodies (TRAb) concentrations were determined with a second-generation enzyme immunoassay (Medizym T.R.A., Medipan GmbH, Dahlewitz/Berlin, Germany). A value of TRAb ≥1.5 IU/l was considered positive. The analytical sensitivity of the assay was 0.5 IU/l. Serum thyroid peroxidase antibodies (TPOAb) were measured using radioimmunoassay (Immunotech, Prague, Czech Republic). A cut-off value of TPOAb ≥20 IU/ml was considered positive. The analytical sensitivity was 2 IU/ml.

*Statistical analysis*: Continuous variables are reported as mean ± standard deviation (SD) or median (inter-quartile range). The Student\'s *t* test or Mann-Whitney U test was used for comparison of continuous variables as appropriate. The chi-square test was used to compare categorical variables. Univariate binary logistic regression analysis was performed to study the presence or absence of GO (dependent variable) with various risk factors including age at onset of GD, gender, current smoking (in males only), domestic smoke exposure, serum T4 and T3, TRAb titre and TPOAb titre. Risk factors were analyzed as follows: age at onset (in units of 10 years), T4 (units of 10 nmol/l), T3 (units of 1 nmol/l), TRAb and TPOAb (highest vs. lowest quartile). Variables which were significant in univariate analysis were included in a forward multiple logistic regression analysis. A two-tailed *P* value \<0.05 was considered significant. Statistical analyses were performed using the SPSS software package (version 15.0; SPSS Inc., Chicago, IL, USA).

Results {#sec1-2}
=======

The baseline characteristics of the patients are summarized in [Table I](#T1){ref-type="table"}. All patients belonged to the State of Uttar Pradesh or adjoining regions. The patients had a median age at onset of 36 yr (inter-quartile range 29-45 yr) and 161 (69%) were females. Thirteen (18%) males were current smokers (median 5 pack-years, range 2-45 pack-years) while five were ex-smokers (stopped for \>12 months). None of the females gave a history of smoking. Environmental smoke exposure due to domestic wood fuel use was elicited in 40 (17%) of patients. GD was newly diagnosed in 53 (23%) patients, 81 (34%) had a duration \<6 months and 101 (43%) patients presented with relapse of GD. Most patients 231 (98%) were on carbimazole and only 2 (1%) had received radioactive iodine. At the time of enrolment, 178 (76%) patients were thyrotoxic, 47 (20%) euthyroid and 10 (4%) hypothyroid on therapy. Graves' dermopathy and acropachy were rare (3 and 1 patient, respectively). Associated autoimmune disease was present in 7 (3%) and family history of autoimmune thyroid disease in 22 (9%) cases.

###### 

Characteristics of Graves' disease (GD) with and without ophthalmopathy
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GO was present in 65 patients (prevalence 28%, 95% CI 22-33%). If lower lid retraction was also included as a diagnostic criterion, the number of subjects with GO (n=75) increased to 32 per cent. The prevalence was similar in males (28%, 95% CI 18-39%) and females (27%; 95% CI 20-34%). The female: male ratio in GO was 2.1:1, which was similar to the ratio in GD (2.2:1).

Subjects with GO had an earlier age at onset of GD as compared with patients without GO (33 vs. 38 yr, *P* \<0.05) ([Table I](#T1){ref-type="table"}). The onset of GO was simultaneous with onset of GD in 49 (75%), within the preceding 12 months in 6 (10%) and after 12 months in 10 (15%) of cases.

The ophthalmological findings in patients with GO are shown in [Table II](#T2){ref-type="table"}. GO was bilateral in 97 per cent (n=63) of patients. Upper eyelid retraction was the most common manifestation 54 (83%), followed by exophthalmos 49 (75%) and soft tissue involvement 26 (40%). Extra-ocular muscle involvement 3 (5%) and optic nerve dysfunction 1 (2%) were uncommon. GO was mild in 54 cases (83%), moderate-severe in 10 (15%) and sight-threatening (due to optic nerve dysfunction) in only 1 patient (2%). Most patients 63 (97%) had clinically inactive GO, of whom 32 (49%) had a CAS of 1-2. Only two patients (3%) had active GO with CAS 4 and 5 and required immunosuppressive therapy with systemic steroids.

###### 

Clinical characteristics of Graves' ophthalmopathy in north Indians
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*TRAb and TPO antibodies*: TRAb were detected in 210 (89%) GD patients ([Table I](#T1){ref-type="table"}). Median TRAb titres were significantly higher in patients with GO as compared to those without GO (29.4 IU/l vs. 7.1 IU/l, *P* \<0.001). The prevalence of GO progressively increased with increasing TRAb titres ([Figure](#F1){ref-type="fig"}). However, median TRAb titres did not differ between patients with moderate-severe and mild disease (18.3 vs. 29.6 IU/l). TPOAb positivity was detected in 87 per cent of patients with GD. Median titers of TPOAb were similar in patients with or without GO ([Table I](#T1){ref-type="table"}).

![Prevalence of Graves' ophthalmopathy in relation to TRAb titres. GO, Graves' ophthalmopathy; TRAb, thyrotropin receptor antibodies; TRAb titres: Quartiles: \<3.5 IU/l, 3.5-12.5 IU/l, 12.5-40 IU/l, \>40 IU/l. Prevalence in quartile, *P* \<0.01 (chi-square test).](IJMR-139-99-g003){#F1}

*Risk factors for GO*: The prevalence of GO in males was higher in current smokers (*i.e*. within 1 year of assessment of \> 2 pack-years) than non-smokers (56 vs. 23%, *P* \<0.05). Current smoking (*i.e*. within 1 year of assessment of \> 2 pack-years) was associated with a 3.9-fold (95% CI 1.1-13.6) risk of GO. However, the severity of GO did not differ between smokers and non-smokers (prevalence of moderate-severe GO 14 vs.17%, respectively). Also, there was no association of wood smoke inhalation and GO. On univariate logistic regression analysis, taking GO as a categorical variable, a younger age at onset of GD, TRAb titre, and current smoking (only assessed in males) were positively associated with GO ([Table III](#T3){ref-type="table"}). On multivariate logistic regression analysis, which included all patients with GD, only TRAb titres were positively associated with GO (OR for highest vs. lowest quartile 6.1, 95% CI 2.4 -15.6, *P* \<0.001). On a multivariate analysis performed only in males, current smokers had a significantly higher risk of GO vs. non-smokers (OR 3.9; 95% CI 1.1-13.6, *P*=0.03).

###### 

Logistic regression analysis of Graves' ophthalmopathy (GO) in north Indians with Graves' disease
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Discussion {#sec1-3}
==========

In the current study of 235 consecutive north Indian subjects with GD presenting to a single center, the prevalence of GO was similar to that described in Caucasians of European descent[@ref7], but the disease was clinically inactive and of mild severity in most instances.

Among patients with GD, the prevalence of GO varies widely in different ethnic groups, with frequencies ranging from 8-56 per cent[@ref7][@ref8][@ref11][@ref17]. These studies have used different clinical settings and diagnostic criteria for GO and comparisons between studies must be interpreted cautiously. The prevalence of GO documented in our study (28%), was similar to previous studies in white patients (25-50%)[@ref7][@ref17]. In a previous study from the United Kingdom which included 39 Indians, a lower prevalence of GO was reported in Indians (8%) as compared to Europeans (42%)[@ref7]. In a retrospective study on surgically treated Indian patients with GD, GO was noted in 58 per cent[@ref18]. However, there was a significant bias in this study as GO formed a major indication for thyroid surgery. In another report, the prevalence of GO was 40 per cent among Indians residing in Malaysia. However, only 10 Indian subjects were included in this study[@ref11].

In our study the disease was mild in most patients with GO (83%) and of moderate or sight-threatening severity was seen in only 15 and 2 per cent patients, respectively. Only 3 per cent patients had clinically active disease requiring immunosuppressive therapy. In contrast, the EUGOGO described 152 European patients with GO where 28 per cent had severe and 33 per cent moderate disease[@ref10]. The disease was clinically active in 60 per cent. In a report of 159 German patients with GO followed for 12 months, 53 per cent had severe disease and 84 per cent were treated with steroids[@ref19]. Possible explanations for the reduced severity of GO in our patients could be lower prevalence of smoking and prior radioactive iodine use. However, since smokers in our study had a similar severity of GO compared to non-smokers, genetic susceptibility is also likely to play a role. It is unlikely that the decreased severity is due to a referral bias since all patients seen in the ophthalmology department were also referred to the Endocrinology clinic. The severity of GO/CAS is known to vary with the duration of the disease. However, since most of our patients were unable to provide an accurate time of onset of eye symptoms, we did not include this variable in our analysis for CAS.

Variability in clinical presentation of GO has been noted in different ethnic groups. Upper eyelid retraction, exophthalmos and soft tissue involvement were the common manifestations of GO in our study, which was consistent with a prior study in Indians[@ref20]. Diplopia (5%) was uncommon in our study when compared to a previous report in Caucasians[@ref9]. In a multi-ethnic Asian study, exophthalmos and lower lid retraction were the most common signs[@ref11]. In contrast, soft tissue inflammatory signs were observed with greatest frequency (75%) in the EUGOGO study[@ref10]. The reason for this variability is unclear.

Among various environmental factors associated with increased risk of GO, smoking has been consistently noted[@ref4][@ref5][@ref7]. While the prevalence of cigarette smoking observed in our patients was low, male smokers had a high risk of GO on multivariate logistic regression analysis. This risk was similar to that reported in previous studies in other Caucasians[@ref3][@ref4]. However, an association of smoking with greater severity of GO was not apparent, possibly because of small number of patients with GO who were current smokers.

As noted in studies in other ethnic groups, higher TRAb titres were found in patients and GD with GO as compared to those without ophthalmopathy[@ref3][@ref19][@ref21]. A progressively increasing prevalence of GO was observed with increasing TRAb titres and TRAb titres were independent risk factor for GO. In contrast to a prior Asian study, TPOAb negativity was not associated with GO in our study[@ref21].

The current study was conducted on patients presenting to an academic referral center which receives a broad and representative spectrum of patients with GD for management. Hence, while it is possible that the features of GO noted may not be fully representative of that in the community, it is likely that they will not differ greatly from that seen in general practice.

In conclusion, our results indicated that while the prevalence of GO in north Indians patients with GD seen at our referral center was similar to that reported in the Caucasians of European origin, clinically active and severe GO was uncommon. Further studies are needed to ascertain if these differences are a result of genetic or environmental differences in these racial groups.
